Queen's Policy Engagement

An increasing number of countries are banning e-cigarettes – here’s why

To date, over 20 countries have banned the sale of e-cigarette products. Professor Lorraine Martin and Dr James Reihill explore the potential harm of e-cigarettes and argue that vaping is not a safe alternative to smoking tobacco.

An increasing number of countries are banning e-cigarettes – here’s why

The White House recently announced plans to ban flavoured e-cigarettes – except for tobacco-flavoured products – because of a rise in the number of middle and high school students using these products.

A few days later, India’s cabinet approved an emergency order banning the production, import and sale of e-cigarettes.

To date, over 20 countries, mostly in South America, the Middle East and South-East Asia, have banned the sale of e-cigarette products. Some countries have also banned possession of these products. Thailand has the strictest laws, while countries such as Australia, Canada and Norway have introduced many restrictions.

Research suggests that e-cigarettes may help smokers quit regular cigarettes benefiting their long-term health. But young people who have never smoked traditional cigarettes are taking up e-cigarettes, which are available in over 1,500 flavours, including bubble gum and candy floss. In a survey of US youths aged 12-17, 81% of e-cigarette users reported that the first product they ever used was flavoured and that they use e-cigarettes because “they come in flavors I like”.

According to the US Centers for Disease Control and Prevention (CDC) over 3.6m children in the US use e-cigarettes, with a jump of 78% (from 11.7% to 20.8%) of US high school students reporting e-cigarette use from 2017 to 2018. And in the UK, 1.6% of those aged 11-18 use e-cigarettes more than once a week, compared with 0.5% in 2015.

Because of the highly addictive nature of nicotine, there is a risk that young e-cigarette users might switch to using traditional cigarettes. Indeed, some healthcare professionals refer to e-cigarettes as a “gateway drug”.

To continue reading, please click here.

Article originally appeared in The Conversation.

 

The featured image has been used courtesy of a Creative Commons license. 

Professor Lorraine Martin and Dr James Reihill
Posted by

Lorraine Martin is a Professor in the School of Pharmacy. Her research interests include the role of active proteases in health and disease which includes the profiling, delineation and inhibition of proteases involved in infection and inflammation. Dr James Reihill is a Senior Research Fellow in the School of Pharmacy.

Leave a Reply

Your email address will not be published. Required fields are marked *